parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in pituitary stem cells	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 105	0.91
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 15050

ZFHX4 in dopamine neurons, braak+0.35 (p 0.354) → -0.16 (p 0.685)receipt 15058
ZFHX4 in astrocytes, braak+0.24 (p 0.535) → +0.02 (p 0.964)receipt 15057

receipt 15058: ZFHX4 in dopamine neurons, braak

power: full sample +0.06 (p 0.827, n 18), 95% CI -0.42 to +0.51. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.06 (p 0.814, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.09 (p 0.709, n 18). could be the mix.
skeptic: leave-one-out range -0.05 to +0.18, sign flips 5; without severely affected donors +0.06 (p 0.827, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ZFHX4 in dopamine neurons.

case closed: nothing better to follow up.

receipt 15057: ZFHX4 in astrocytes, braak

power: full sample +0.11 (p 0.664, n 18), 95% CI -0.38 to +0.55. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.09 (p 0.709, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.05 (p 0.847, n 18). could be the mix.
skeptic: leave-one-out range +0.00 to +0.28, sign flips 0; without severely affected donors +0.11 (p 0.664, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ZFHX4 in astrocytes.

case closed: nothing better to follow up.

loading the receipts